Key facts
- Nitinotes’s last known valuation is $12.1M (Sep 2023).
- It has raised $34.0M; the latest was Later Stage VC ($9.3M) in Dec 2024.
- Notable investors include MedTech Innovator, Arkin Capital, Peregrine Ventures, Arieli Group, Elron Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Nitinotes
- ·The full record, as it builds
Funding rounds
No funding rounds for Nitinotes are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nitinotes
Developer of a minimally invasive suturing system designed to be used for safer and simpler gastrointestinal suturing. The company offers an automated endoluminal suturing system with consistent and reproducible delivery, intuitive operation, reduced procedural time, and broad clinical trial support, enabling gastrointestinal and bariatric care teams to perform advanced endoscopic gastroplasty with improved access for patients seeking less invasive obesity treatment and reliable clinical outcomes.
- Sector
- Healthcare
- HQ
- Caesarea, Israel
- Founded
- 2014
- Employees
- 35
- Website
- nitinotesurgical.com/
- Ownership
- Privately Held (backing)
Nitinotes doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nitinotes shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nitinotes in its N-PORT filings yet. We sweep new filings monthly.